セッション詳細
[WS(P)03]In vivo model and new cancer immunotherapy
2024年12月3日(火) 16:50 〜 17:35
Poster 3
[WS03-01-O/P]LAG-3 blockade reactivates the CD8+ T cell expansion program to re-expand contracted clones in the tumor
○Munetomo Takahashi1, Mikiya Tsunoda2, Shigeyuki Shichino2, Shumpei Ishikawa1, Kouji Matsushima2, Satoshi Ueha2 (1.Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, 2.Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science)
[WS03-02-P]A novel biparatopic TIM-3 antibody induces superior antitumor effects through multi-ligand blockade
○Kanto Nakajima1, Yuji Mishima1, Motoya Mie1, Norihiro Nakamura1, Junichiro Yuda2 (1.BrightPath Biotherapeutics Co., Ltd., 2.Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East)
[WS03-03-P]Combination therapy of proton beam irradiation and PD-L1 inhibitor induced an immune response in murine models of pancreatic cancer
○Tuyen Thuy Bich Ho1, Alessandro Nasti1, Akihiro Seki2, Yoshio Sakai2, Kosuke Satomura3, Kyo Kume4, Munetoshi Maeda4, Hiroyasu Tamamura5, Makoto Sasaki5, Kazutaka Yamamoto5, Taro Yamashita2,3, Shuichi Kaneko1,2,3 (1.Information-Based Medicine Development, Graduate School of Medical Sciences, Kanazawa University, 2.Department of Gastroenterology, Kanazawa University Hospital, 3.System biology, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, 4.Proton Medical Research Division, Research & Development Department, The Wakasa Wan Energy Research Center, 5.Proton Therapy Center, Fukui Prefectural Hospital)
[WS03-04-P]Trastuzumab Deruxtecan (T-Dxd), the novel HER2 Antibody-drug-conjugates regulates anti-tumor activity against HER2+ CCA via multiple mechanisms.
○Prin Sungwan1, Jutatip Panaampon1,2, Seiji Okada1 (1.Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University, Japan, 2.Division of Hematologic Neoplasia, Dept. of Med. Oncology, Dana-Farber Cancer Inst., Harvard Med. Sch.,450 Brookline Avenue, Boston, Massachusetts (MA), 02215, USA)
[WS03-05-P]Analysis of the combination effects of cytotoxic chemotherapy and PD-1 blockade therapy using PD-1 fate-tracer mise
○Ayuko Yamaguchi1,2, Haruka Suzuki1,2, Megumi Tatematsu1, Shunsuke Takasuga1, Akane Fuchimukai1, Takashi Ebihara1,3 (1.Department of Microbiology, Akita University Graduate School of Medicine, 2.Department of Thoracic Surgery, Akita University Graduate School of Medicine, 3.Center for Integrated Control, Epidemiology and Molecular Pathophysiology of Infectious Diseases, Akita University)
[WS03-06-O/P]PQDN improves CD8+ T cell metabolism by mitochondrial tuning resulting in improved cancer immunotherapy
○Huimin Sun1, Yosuke Dotsu1, Daisuke Muraoka1,2, Daisuke Kato4, Naohisa Ogo3, Yudai Sonoda3, Situo Deng1, Kiyoshi Yasui1, Mitsuhiro Yoneda1, Hiromu Kondo4, Akira Asai3, Hiroaki Ikeda1 (1.Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2.Division of Translational Oncoimmunology, Aichi Cancer Research Institute, Nagoya, Japan, 3.Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan, 4.Department of Pharmaceutical Engineering and Drug Delivery Science, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan)
[WS03-07-P]Robust pancreatic tumor suppression by a novel combination treatment with anti-PD-1 immune checkpoint antibody and stroma modifying RNA oligonucleotide STNM01 in mice
○Juanjuan Ye1,2, Futoshi Suizu1, Keiko Yamakawa1, Yuri Mukai1, Akira Nishiyama2, Hiroyuki Yoneyama3, Takayoshi Tsuchiya4, Motohiko Kato5, Naohisa Yahagi6, Kyuichi Kadota1 (1.Molecular Oncologic Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, 2.Pharmacology, Department of Morphological and Functional Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan., 3.TME Therapeutics Inc. Minato-ku, Tokyo, Japan., 4.Tokyo Medical University, Shinjuku-ku, Tokyo, Japan., 5.Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan., 6.Divison of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.)
[WS03-08-O/P]Cystatin A enhances CD4+ T cells and M1 macrophages antitumor activity in murine models of pancreatic cancer
○Alessandro Nasti1, Shingo Inagaki2, Tuyen Thuy Bich Ho1, Akihiro Seki3, Keiko Yoshida2, Kosuke Satomura2, Taro Yamashita2,3, Yoshio Sakai2, Shuichi Kaneko1,2,3 (1.Information-Based Medicine Development, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan., 2.System biology, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, Japan., 3.Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.)
[WS03-09-P]Immune checkpoint inhibitory activity of Hericium erinaceus mycelia obtained from liquid media using food by-products
○Hajime Kobori1,2, Taro Yasuma3, Masaaki Toda3, Kazuhiko Masuno4, Hirokazu Kawagishi2,5, Corina N. D'Alessandro-Gabazza3, Esteban C. Gabazza3 (1.Iwade Research Institute of Mycology Co., Ltd, 2.Research Institute for Mushroom Science, Shizuoka University, 3.Department of Immunology, Mie University School of Medicine, 4.Nagano Prefecture General Forest Research Center, 5.Faculty of Agriculture, Shizuoka University)
[WS03-10-O/P]Synergistic Effects of Immune Checkpoint Inhibition Therapy with Lactobacillus Metabolites
○Takumi Iwasawa1,2,3, Suguru Yamauchi4, Tomoaki Ito3,5, Kazunori Kato1,2 (1.Inst. of Life Innova. Stu., Toyo Univ., 2.Grad. Sch Heal. & Sports Sci., Toyo Univ., 3.Shizuoka Med. Res. Center for Disast., Juntendo Univ., 4.Dept. Surg., Johns Hopkins Univ., 5.Dept. Surg., Shizuoka Hospital, Juntendo Univ.)
[WS03-11-O/P]Complete humanization of MHC region in mouse
○Teruhiko Suzuki1, Mana Yamakawa1, Saki An1, Hiroko Yanagisawa1, Yasuhiro Kazuki2,3,4,5, Mitsuo Oshimura2, Eiji Mizutani6, Takahiko Hara1,7,8 (1.Stem Cell Proj., Tokyo Metropol. Inst. Med. Sci., 2.CERC, Tottori Univ., 3.Div. of Chr. Biomed. Eng., Grad. Sch. of Med. Sci., Tottori Univ., 4.Chr. Eng. Group, ExCELLS., 5.Sch. of Life Sci., Facul. of Med., Tottori Univ., 6.Institute of Medicine, University of Tsukuba, 7.Grad. Sch., Tokyo Med. Dent. Univ., 8.Grad. Sch., Tokyo Metropol. Univ.)
[WS03-12-P]An attempt for generation of homozygous MHC humanized cells and mice
○Yuka Egawa1,2, Mana Yamakawa1, Saki An1, Hiroko Yanagisawa1, Yasuhiro Kazuki3,4,5,6, Mitsuo Oshimura3, Takahiko Hara1,2,7, Teruhiko Suzuki1, Eiji Mizutani8 (1.Stem Cell Proj., Tokyo Metropol. Inst. Med. Sci., 2.Grad. Sch., Tokyo Metropol. Univ., 3.CERC, Tottori Univ., 4.Div. of Chr. Biomed. Eng., Grad. Sch. of Med. Sci., Tottori Univ., 5.Chr. Eng. Group, ExCELLS., 6.Sch. of Life Sci., Facul. of Med., Tottori Univ., 7.Grad. Sch., Tokyo Med. Dent. Univ., 8.Institute of Medicine, University of Tsukuba)
[WS03-13-O/P]Anti-tumor effect of a human SIRPα antibody targeting human macrophages in a humanized mouse model
○Tania Afroj1, Satomi Komori1, Ikumi Katano2, Takeshi Takahashi2, Takenori Kotani1, Yoji Murata1, Takashi Matozaki1, Yasuyuki Saito1 (1.Kobe University Graduate School of Medicine, 2.Central Institute for Experimental Animals, Kawasaki, Japan)
[WS03-14-P]Establishment of Inducible Disruption of Bioactive Lipid Receptors on Neutrophils Using an In Vivo Degron System.
○Kiyokazu Kakugawa1, Priyanka Saminathan2, Ian Mathews2,4, Loutje Van Der Sman2, Maija Corey2, Mohit Jain3,4, Sonia Sharma1,2 (1.Laboratory for inflammatory Immune Metabolism, RIKEN-IMS, Yohokohama, Japan., 2.La Jolla Institute for Immunology, La Jolla, CA 92037, 3.Sapient Bioanalytics, San Diego CA 92121, 4.Department of Medicine, University of California San Diego, La Jolla CA 92093)
[WS03-15-P]Intravital visualization of immune cell responses after anticancer small molecule drug treatment
○Junyoung Park, Hyunseok Kim, Hyungjin Kwon (IVIM Technology)